Lipid-lowering drugs.

• HIRAKAWA Yoji

  Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences

• SHIMOKAWA Hiroaki

  Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences

Bibliographic Information

Other Title

• 高脂血症治療薬
• 新薬開発状況 高脂血症治療薬
• シンヤク カイハツ ジョウキョウ コウシケツショウ チリョウヤク

Abstract

Accumulating evidences in recent major clinical studies have shown the importance of anti-hyperlipidemic treatment in preventing atherosclerotic cardiovascular diseases. Lipid-lowering drugs can be divided into HMG-CoA reductase inhibitors (statins), bile-acid sequestrants (resins), nicotinic acid, fibrates and probucol. Among them, statins had revolutionary impact on the treatment of hyperlipidemia since pravastatin, which was developed in Japan, was launched in 1989. Several lipid-lowering drugs are now under development in Japan, including pitavastatin, rosuvastatin, F-1394 (ACAT inhibitor), CS-505 (ACAT inhibitor) and NO-1886 (LPL activator). In this review, characteristics of these new lipid-lowering drugs will be discussed.

Journal

• Folia Pharmacologica Japonica

  Folia Pharmacologica Japonica 118 (6), 389-395, 2001

  The Japanese Pharmacological Society

Keywords

• pitavastatin
• rosuvastatin
• gemfibrozil
• F-1394
• NO-1886

Details

• CRID: 1390001204272656256
• NII Article ID: 10008181492
• NII Book ID: AN00198335
• DOI: 10.1254/fpj.118.389
• COI: 1:CAS:528:DC%2BD38XjsVyitQ%3D%3D
• ISSN: 13478397
• ISSN: 00155691
• NDL BIB ID: 5995094
• PubMed: 11778457
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I5995094
• Web Site: https://www.jstage.jst.go.jp/article/fpj/118/6/118_6_389/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2002149915
• Text Lang: ja
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• Abstract License Flag: Disallowed